Switching to exemestane after 2-3 years of adjuvant tamoxifen prolongs disease-free survival, but not overall survival, in postmenopausal women surviving primary breast cancer, compared with continuous tamoxifen

被引：0
|
作者：
Davies, C [1 ]
机构：
[1] Univ Oxford, Studies Unit, Clin Trial Serv & Epidemiol, Oxford, England
来源：
CANCER TREATMENT REVIEWS | 2004年 / 30卷 / 06期
关键词：
D O I：
10.1016/j.ctrv.2004.06.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：583 / 588
页数：6
相关论文
共 50 条
  • [41] A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER: CANADIAN PERSPECTIVE
    El Ouagari, K.
    Kaura, S.
    Karnon, J. D.
    VALUE IN HEALTH, 2009, 12 (07) : A279 - A279
  • [42] Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer
    Gogate, Anagha
    Ranjan, Sandip
    Kumar, Amit
    Bhandari, Hitesh
    Papademetriou, Eros
    Kim, Inkyu
    Potluri, Ravi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [43] Comparison of the cost per distant disease-free year gained for upfront letrozole or anastrozole, or switched exemestane compared to tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: The UK perspective
    Karnon, J.
    di Trapani, F.
    Kaura, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen
    Moyer, Ann M.
    Suman, Vera J.
    Weinshilboum, Richard M.
    Avula, Rajeswari
    Black, John L.
    Safgren, Stephanie L.
    Kuffel, Mary J.
    Ames, Matthew M.
    Ingle, James N.
    Goetz, Matthew P.
    PHARMACOGENOMICS, 2011, 12 (11) : 1535 - 1543
  • [45] Breast-conserving surgery improves the outcomes of disease-free survival and overall survival in young women with breast cancer (≤35 years): A retrospective study based on surgical options
    Li, Pei
    Li, Lun
    Xue, Jingyan
    Wu, Jiong
    CANCER RESEARCH, 2022, 82 (04)
  • [46] DISEASE-FREE SURVIVAL (DFS) AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL (OS) IN HER2 NEGATIVE (HER2-) PRIMARY BREAST CANCER (BC)
    McCrea, C.
    Chatzidaki, I
    Drane, E.
    McArthur, E.
    Beaver, S.
    Reason, T.
    Gulati, P.
    VALUE IN HEALTH, 2020, 23 : S425 - S425
  • [47] Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
    Jakesz, R
    Jonat, W
    Gnant, M
    Mittlboeck, M
    Greil, R
    Tausch, C
    Hilfrich, J
    Kwasny, W
    Menzel, C
    Samonigg, H
    Seifert, M
    Gademann, G
    Kaufmann, M
    LANCET, 2005, 366 (9484): : 455 - 462
  • [48] Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006
    Ng, R.
    Pond, G. R.
    Tang, P. A.
    MacIntosh, P. W.
    Siu, L. L.
    Chen, E. X.
    ANNALS OF ONCOLOGY, 2008, 19 (03) : 481 - 486
  • [49] Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer
    Lonning, PE
    ANNALS OF ONCOLOGY, 2006, 17 (02) : 217 - 225
  • [50] High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients
    Kong, Yanan
    Dai, Shuqin
    Xie, Xinhua
    Xiao, Xiangsheng
    Lv, Ning
    Guo, Jiaoli
    Li, Laisheng
    Jia, Weihua
    Zhang, Yin
    Liu, Wanli
    Wei, Weidong
    Xie, Xiaoming
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (02) : 275 - 284
12345